Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents

Journal of Medicinal Chemistry

Volumn 58, Issue 4, 2015, Pages 1992-2002

  Cheng, Jianjun ^a   Giguère, Patrick M ^b   Onajole, Oluseye K ^a,e   Lv, Wei ^a   Gaisin, Arsen ^a,f   Gunosewoyo, Hendra ^a,g   Schmerberg, Claire M ^c   Pogorelov, Vladimir M ^c   Rodriguiz, Ramona M ^c   Vistoli, Giulio ^d   Wetsel, William C ^c   Roth, Bryan L ^b   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e ROOSEVELT UNIVERSITY   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC AMINE; AMPHETAMINE; LORCASERIN; NEUROLEPTIC AGENT; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; TERT BUTYL [[2 [2 (ALLYLOXY) 5 FLUOROPHENYL]CYCLOPROPYL]METHYL]CARBAMATE; TERT BUTYL [[2 [5 FLUORO 2 (2 FLUOROETHOXY)PHENYL] CYCLOPROPYL]METHYL]CARBAMATE; UNCLASSIFIED DRUG; [2 [2 (ALLYLOXY) 5 FLUOROPHENYL]CYCLOPROPYL]METHANAMINE HYDROCHLORIDE]; [2 [5 FLUORO 2 (2 FLUOROETHOXY)PHENYL] CYCLOPROPYL]METHANAMINE HYDROCHLORIDE]; (2-(2-(ALLYLOXY)-5-FLUOROPHENYL)CYCLOPROPYL)METHANAMINE; ALLYL COMPOUND; CYTOCHROME P450; METHYLAMINE; SEROTONIN 2 AGONIST;

AEROBIC METABOLISM; ANIMAL CELL; ARTICLE; AUTOMATED PATCH CLAMP; CHIRALITY; CONTROLLED STUDY; DEPROTECTION REACTION; DRUG DESIGN; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGEN BOND; HYPERACTIVITY; IN VITRO STUDY; LIPOPHILICITY; LIVER MICROSOME; MITSUNOBU REACTION; MOUSE; NONHUMAN; OPTICAL ROTATION; PLASMA PROTEIN BINDING; STEREOCHEMISTRY; STEREOSPECIFICITY; WILLIAMSON REACTION; ANIMAL; C57BL MOUSE; CACO 2 CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; LOCOMOTION; MALE; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ALLYL COMPOUNDS; AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; CACO-2 CELLS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LOCOMOTION; MALE; METHYLAMINES; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84923870056     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5019274     Document Type: Article

References (32)

1. Berger, M.; Gray, J. A.; Roth, B. L. The expanded biology of serotonin Annu. Rev. Med. 2009, 60, 355-366
2. Nichols, D. E.; Nichols, C. D. Serotonin receptors Chem. Rev. 2008, 108, 1614-1641
3. Meltzer, H. Y.; Roth, B. L. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs J. Clin. Invest. 2013, 123, 4986-4991
4. Smith, B. M.; Thomsen, W. J.; Grottick, A. J. The potential use of selective 5-HT2C agonists in treating obesity Expert Opin. Invest. Drugs 2006, 15, 257-266
5. Sargent, B. J.; Henderson, A. J. Targeting 5-HT receptors for the treatment of obesity Curr. Opin. Pharmacol. 2011, 11, 52-58
6. Rosenzweig-Lipson, S.; Comery, T. A.; Marquis, K. L.; Gross, J.; Dunlop, J. 5-HT(2C) agonists as therapeutics for the treatment of schizophrenia Handb. Exp. Pharmacol. 2012, 147-165
7. Mombereau, C.; Kawahara, Y.; Gundersen, B. B.; Nishikura, K.; Blendy, J. A. Functional relevance of serotonin 2C receptor mRNA editing in antidepressant- and anxiety-like behaviors Neuropharmacology 2010, 59, 468-473
8. Pazos, A.; Hoyer, D.; Palacios, J. M. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site Eur. J. Pharmacol. 1984, 106, 539-546
9. Berg, K. A.; Clarke, W. P.; Cunningham, K. A.; Spampinato, U. Fine-tuning serotonin 2c receptor function in the brain: molecular and functional implications Neuropharmacology 2008, 55, 969-976
10. Nichols, D. E. Hallucinogens Pharmacol. Ther. 2004, 101, 131-181
11. Lee, J.; Jung, M. E.; Lee, J. 5-HT2C receptor modulators: a patent survey Expert Opin. Ther. Pat. 2010, 20, 1429-1455
12. Thomsen, W. J.; Grottick, A. J.; Menzaghi, F.; Reyes-Saldana, H.; Espitia, S.; Yuskin, D.; Whelan, K.; Martin, M.; Morgan, M.; Chen, W.; Al-Shamma, H.; Smith, B.; Chalmers, D.; Behan, D. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization J. Pharmacol. Exp. Ther. 2008, 325, 577-587
13. Lorcaserin. In obesity: unacceptable risks. Prescrire Int. 2014, 23, 117-120.
14. Liu, J.; Ogden, A.; Comery, T. A.; Spiros, A.; Roberts, P.; Geerts, H. Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model CPT Pharmacometrics Syst. Pharmacol. 2014, 3, e111
15. Dunlop, J.; Watts, S. W.; Barrett, J. E.; Coupet, J.; Harrison, B.; Mazandarani, H.; Nawoschik, S.; Pangalos, M. N.; Ramamoorthy, S.; Schechter, L.; Smith, D.; Stack, G.; Zhang, J.; Zhang, G.; Rosenzweig-Lipson, S. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist J. Pharmacol. Exp. Ther. 2011, 337, 673-680
16. Marquis, K. L.; Sabb, A. L.; Logue, S. F.; Brennan, J. A.; Piesla, M. J.; Comery, T. A.; Grauer, S. M.; Ashby, C. R., Jr.; Nguyen, H. Q.; Dawson, L. A.; Barrett, J. E.; Stack, G.; Meltzer, H. Y.; Harrison, B. L.; Rosenzweig-Lipson, S. WAY-163909 [(7b R,10a R)-1,2,3,4,8,9,10,10a-octahydro-7b H -cyclopenta-[ b ][1,4]diazepino[6,7,1- hi ]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity J. Pharmacol. Exp. Ther. 2007, 320, 486-496
17. Siuciak, J. A.; Chapin, D. S.; McCarthy, S. A.; Guanowsky, V.; Brown, J.; Chiang, P.; Marala, R.; Patterson, T.; Seymour, P. A.; Swick, A.; Iredale, P. A. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity Neuropharmacology 2007, 52, 279-290
18. Kalgutkar, A. S.; Dalvie, D. K.; Aubrecht, J.; Smith, E. B.; Coffing, S. L.; Cheung, J. R.; Vage, C.; Lame, M. E.; Chiang, P.; McClure, K. F.; Maurer, T. S.; Coelho, R. V., Jr.; Soliman, V. F.; Schildknegt, K. Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation Drug Metab. Dispos. 2007, 35, 848-858
19. Callahan, P. M.; Cunningham, K. A. Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m -chlorophenylpiperazine (mCPP) Eur. J. Pharmacol. 1994, 257, 27-38
20. Fiorella, D.; Helsley, S.; Rabin, R. A.; Winter, J. C. 5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m -chlorophenylpiperazine Psychopharmacology (Berlin, Ger.) 1995, 122, 237-243
21. Cho, S. J.; Jensen, N. H.; Kurome, T.; Kadari, S.; Manzano, M. L.; Malberg, J. E.; Caldarone, B.; Roth, B. L.; Kozikowski, A. P. Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action J. Med. Chem. 2009, 52, 1885-1902
22. Kozikowski, A. P.; Cho, S. J.; Jensen, N. H.; Allen, J. A.; Svennebring, A. M.; Roth, B. L. HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia ChemMedChem 2010, 5, 1221-1225
23. Chen, G.; Cho, S. J.; Huang, X. P.; Jensen, N. H.; Svennebring, A.; Sassano, M. F.; Roth, B. L.; Kozikowski, A. P. Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity ACS Med. Chem. Lett. 2011, 2, 929-932
24. Yamazaki, K.; Kanaoka, M. Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds J. Pharm. Sci. 2004, 93, 1480-1494
25. Aronov, A. M. Predictive in silico modeling for hERG channel blockers Drug Discovery Today 2005, 10, 149-155
26. Turpeinen, M.; Zanger, U. M. Cytochrome P450 2B6: function, genetics, and clinical relevance Drug Metab. Drug Interact. 2012, 27, 185-197
27. Millan, M. J.; Dekeyne, A.; Gobert, A. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo Neuropharmacology 1998, 37, 953-955
28. Di Giovanni, G.; Di Matteo, V.; Di Mascio, M.; Esposito, E. Preferential modulation of mesolimbic vs nigrostriatal dopaminergic function by serotonin (2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study Synapse 2000, 35, 53-61
29. Leysen, J. E. 5-HT2 receptors Curr. Drug Targets: CNS Neurol. Disord. 2004, 3, 11-26
30. Wacker, D.; Wang, C.; Katritch, V.; Han, G. W.; Huang, X. P.; Vardy, E.; McCorvy, J. D.; Jiang, Y.; Chu, M.; Siu, F. Y.; Liu, W.; Xu, H. E.; Cherezov, V.; Roth, B. L.; Stevens, R. C. Structural features for functional selectivity at serotonin receptors Science 2013, 340, 615-619
31. Marti-Renom, M. A.; Stuart, A. C.; Fiser, A.; Sanchez, R.; Melo, F.; Sali, A. Comparative protein structure modeling of genes and genomes Annu. Rev. Biophys. Biomol. Struct. 2000, 29, 291-325
32. Korb, O.; Stutzle, T.; Exner, T. E. Empirical scoring functions for advanced protein-ligand docking with PLANTS J. Chem. Inf. Model. 2009, 49, 84-96